#ASCO21: Bristol Myers takes home the win in 1st late-stage study for LAG-3 pathway, setting up a US filing
When Bristol Myers Squibb dropped winning late-stage data for its anti-LAG-3 drug in March, the results offered new hope for an immune checkpoint pathway that had long lagged behind its better-known cousins. Now, the drugmaker is rolling out hard numbers on that win, and it looks very promising for an eventual combo approval alongside Opdivo.
A combo of Bristol Myers’ LAG-3 inhibitor relatlimab and PD-1 blocker Opdivo posted a progression-free survival of 10.12 months in patients with metastatic or unresectable melanoma compared with 4.63 months for patients on Opdivo alone, according to data from the Phase II/III RELATIVITY-047 study set to be presented at ASCO in June.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 109,500+ biopharma pros reading Endpoints daily — and it's free.